MYRTO: From Real-World Needs to European Scientific Engagement

MYRTO, the digital Social Rights Navigator developed by Kapa3, is taking an important step from real-world experience to the European scientific community, with two studies accepted for presentation at EONS and ESMO events in 2026.

The first study, “MYRTO as an AI-Supported Navigation Model for Equitable Access to Cancer Care: Real-World Needs from 1,083 Beneficiaries”, will be presented as a poster at EONS19 at ESMO 2026 in Madrid, 24–26 October 2026.

The study draws on the real-world needs of 1,083 Kapa3 beneficiaries, identifying eight key navigation areas: rights and benefits, disability certification and administrative procedures, access to health and social services, transportation and geographical barriers, employment and social protection, health and digital literacy, caregiver support, and referral to human professionals when needed.

The findings highlight that equitable access to cancer care is not only about clinical information. It also depends on people’s ability to find, understand and use reliable information during an exceptionally demanding period of their lives.

From real-world needs to technology evaluation

The second study, “Source-Based Artificial Intelligence (AI) Navigation for Fragmented Nonclinical Cancer-Support Information: Pilot Evaluation of a Human-Supervised System”, has been accepted as an e-Poster at the ESMO AI & Digital Oncology Congress 2026, taking place on 16–18 November 2026.

This study focuses on the operation and evaluation of MYRTO as a source-grounded, human-supervised AI system.

The pilot evaluation drew on 448 authoritative documents and 29,148 indexed excerpts and assessed 100 predefined questions. For all 84 answerable questions, source-supported and actionable responses were generated without modifications following Kapa3 expert review. The system also applied clarification, abstention or redirection mechanisms when evidence was insufficient or when questions involved medical advice or fell outside its intended scope.

Two studies, one shared philosophy

The two studies reflect complementary dimensions of MYRTO: the real-world needs that led to its development and the way technology is being designed to respond to those needs through evidence, clear boundaries and human supervision.

For Kapa3, Artificial Intelligence is not intended to replace human support. Its role is to contribute to more accessible, understandable and trustworthy navigation, while keeping people at the centre.

MYRTO’s presence at two major European scientific events represents another step in bringing Kapa3’s field experience into the European dialogue on equitable access, digital health and the responsible use of Artificial Intelligence.

The MYRTO project is funded by the TIMA Charitable Foundation.

Find more about MYRTO https://kapa3-cag-rag-hybrid-deploy.onrender.com

ESMO Highlights the Importance of Prioritising the Fight Against Cancer in the EU4Health 2026 Work Programme

The European Society for Medical Oncology (ESMO) submitted its response to the public consultation on the 2026 Annual Work Programme of EU4Health, emphasising the urgent need to make cancer a top priority across Europe. With the number of cancer cases projected to rise from over 4.47 million in 2022 to 5.48 million in 2045, ESMO calls for dedicated EU4Health actions to address this growing challenge.

Among the key areas highlighted by ESMO is the importance of improving accessibility to healthcare based on current medical knowledge and international standards, while adequately monitoring the quality of healthcare services to prevent inequalities across the EU. This approach aligns closely with the mission and activities of Kapa3, which aims to ensure equitable access to health support for all, particularly young adults affected by cancer.

Through its initiatives, Kapa3 actively promotes awareness, supports access to quality healthcare, and works to reduce disparities in health services, reflecting the same commitment emphasised by ESMO in its response to EU4Health.

Read more on ESMO’s response, here